Tyme Technologies Inc. (TYME)

[axelvento]

Dosing underway in mid-stage sarcoma study of Tyme's SM-88

The primary endpoints of the open-label 24-subject study are overall response rate (ORR) every three months for up to two years, the proportion of patients with stable cancer for at least three month (up to two years) and the proportion of patients with progression-free survival (PFS) at least 1.5x the duration of PFS for the last prior treatment (every three months for up to two years).

The estimated primary completion date is late October. The estimated final completion date is late October 2022.